These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37835569)

  • 21. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
    Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterization of Gut Microbiota and Exploration of Potential Predictive Model for Hepatocellular Carcinoma Microvascular Invasion.
    Zhang N; Wang Z; Lv J; Zhang S; Liu Y; Liu T; Li W; Gong L; Zhang X; El-Omar EM; Lu W
    Front Med (Lausanne); 2022; 9():836369. PubMed ID: 35372388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics.
    Sydor S; Dandyk C; Schwerdt J; Manka P; Benndorf D; Lehmann T; Schallert K; Wolf M; Reichl U; Canbay A; Bechmann LP; Heyer R
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.
    Gopalakrishnan V; Helmink BA; Spencer CN; Reuben A; Wargo JA
    Cancer Cell; 2018 Apr; 33(4):570-580. PubMed ID: 29634945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review.
    Muscolino P; Granata B; Omero F; De Pasquale C; Campana S; Calabrò A; D'Anna F; Drommi F; Pezzino G; Cavaliere R; Ferlazzo G; Silvestris N; Speranza D
    Front Oncol; 2023; 13():1247614. PubMed ID: 37692859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Microbiome and Liver Cancer.
    Myojin Y; Greten TF
    Cancer J; 2023 Mar-Apr 01; 29(2):57-60. PubMed ID: 36957974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic potential of gut microbiome for early hepatitis B virus-related hepatocellular carcinoma.
    Tang Y; Zhou H; Xiang Y; Cui F
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e167-e175. PubMed ID: 33208683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
    Abenavoli L; Montori M; Svegliati Baroni G; Argenziano ME; Giorgi F; Scarlata GGM; Ponziani F; Scarpellini E
    Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629716
    [No Abstract]   [Full Text] [Related]  

  • 29. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer.
    Deng T; Li J; He B; Chen B; Liu F; Chen Z; Zheng J; Shi Z; Zhang T; Deng L; Yu H; Yang J; Wu L; Shan Y; Yu Z; Chen X; Wang Y; Chen G
    Hepatol Int; 2022 Feb; 16(1):99-111. PubMed ID: 35064546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma.
    Jinato T; Anuntakarun S; Satthawiwat N; Chuaypen N; Tangkijvanich P
    Appl Microbiol Biotechnol; 2024 Dec; 108(1):34. PubMed ID: 38183473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered Gut Microbiota Composition and Its Potential Association in Patients with Advanced Hepatocellular Carcinoma.
    Huo R; Chen Y; Li J; Xu Q; Guo J; Xu H; You Y; Zheng C; Chen Y
    Curr Oncol; 2023 Feb; 30(2):1818-1830. PubMed ID: 36826102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients.
    Chung MW; Kim MJ; Won EJ; Lee YJ; Yun YW; Cho SB; Joo YE; Hwang JE; Bae WK; Chung IJ; Shin MG; Shin JH
    World J Gastroenterol; 2021 Nov; 27(42):7340-7349. PubMed ID: 34876793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
    Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
    Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A longitudinal assessment of host-microbe-parasite interactions resolves the zebrafish gut microbiome's link to Pseudocapillaria tomentosa infection and pathology.
    Gaulke CA; Martins ML; Watral VG; Humphreys IR; Spagnoli ST; Kent ML; Sharpton TJ
    Microbiome; 2019 Jan; 7(1):10. PubMed ID: 30678738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis.
    Liakina V; Strainiene S; Stundiene I; Maksimaityte V; Kazenaite E
    World J Hepatol; 2022 Jul; 14(7):1277-1290. PubMed ID: 36158907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?
    Segal JP; Mak JWY; Mullish BH; Alexander JL; Ng SC; Marchesi JR
    Therap Adv Gastroenterol; 2020; 13():1756284820974914. PubMed ID: 33281941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients.
    Li X; Yi Y; Wu T; Chen N; Gu X; Xiang L; Jiang Z; Li J; Jin H
    Front Cell Infect Microbiol; 2023; 13():1170748. PubMed ID: 37260707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Microbiome and Hepatocellular Carcinoma.
    Rattan P; Minacapelli CD; Rustgi V
    Liver Transpl; 2020 Oct; 26(10):1316-1327. PubMed ID: 32564483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.